In a large trial led by a Stanford investigator, an experimental drug produced clinically meaningful improvements for rheumatoid arthritis patients unresponsive to existing treatments.
Rheumatoid arthritis patients getting little or no relief from conventional small-molecule drugs and injectable biologic drugs saw substantial improvement in their condition from daily use of an experimental compound in a large 24-week study led by a Stanford University School of Medicine investigator
A paper describing the results of the double-blind, randomized phase-3 clinical trial was published July 23 in JAMA.
“For patients who haven’t done well on other therapies, these findings are cause for optimism, enthusiasm and hope,” said Mark Genovese, MD, professor of immunology and rheumatology and principal investigator of the study.
Stanford Health Care offers services to rheumatoid arthritis patients through its immunology and rheumatology clinic. As clinical chief, Genovese spends three half-days per week in the clinic, where he regularly sees and treats rheumatoid arthritis patients.
He is the paper’s lead author. The senior author is Tsutomu Takeuchi, MD, PhD, professor of rheumatology and clinical immunology at Keio University School of Medicine in Tokyo, Japan.
Rheumatoid arthritis is a progressive, systemic autoimmune disease affecting at least 1 in every 100 people worldwide. For reasons that aren’t understood, 3 of every 4 people with the disorder are women. While its most visible hallmarks are pain, stiffness, inflammation and eventual deterioration of joints, patients also are at heightened risk for cardiovascular disease and other inflammatory complications.
In clinical trials, about 70% of rheumatoid arthritis patients have appeared to benefit initially from small-molecule therapies in a pill form, such as methotrexate, said Genovese, who is the James W. Raitt M.D. Professor. However, “in the real world, adherence to any of them is more like 50%,” he said. Patients for whom the conventional small-molecule drugs fail are switched to pricey, injectable, bioengineered-protein drugs, including three of the world’s top-15 biggest-selling drugs in dollar sales. But these drugs, too, fail among about half the rheumatoid arthritis patients who use them, Genovese said.
Selective JAK-1 inhibitor
The experimental compound, filgotinib, is a selective JAK-1 inhibitor. It works by preferentially blocking 1 of a set of 4 closely related enzymes required for certain inflammatory signaling processes within cells. Two other compounds that are similar in mechanism of action to filgotinib but that impede JAK enzyme family members less selectively are licensed in the United States for use by rheumatoid arthritis patients, but only at low doses or with warning labels due to side effects.
This novel drug works exceptionally well in patients who’ve already failed traditional therapies for rheumatoid arthritis.
The trial was conducted in 114 centers in 15 countries, mostly in North America and Europe. The 449 participants averaged 56 years of age, and about 80% of them were female. They were randomized to 1 of 3 study arms, in which they received daily doses of either 200 milligrams of filgotinib, 100 milligrams of filgotinib or a placebo for 24 weeks. All participants had moderately to severely active rheumatoid arthritis despite treatment with one or more biologic therapies.
The primary goal of the study was to observe whether there was an improvement at 12 weeks into the trial of at least 20% on a measure of joint swelling and tenderness called the ACR20 that was established by the American College of Rheumatology. An important secondary outcome was a score indicating low disease activity in 28 predetermined joints on a test called the DAS28-CRP.
Compared with the placebo group, a significantly greater proportion of participants on both the high- and low-dose filgotinib regimens achieved the primary endpoint: a 20% improvement in symptoms as measured by the ACR20. Sixty-six percent of participants on 200 milligrams of filgotinib, and 57.5% of those on 100 milligrams, fulfilled this criterion, versus only 31.1% of those on placebo.
Of equal or even greater importance, Genovese said, was the participants’ improvement on the DAS28-CRP at both 12 and 24 weeks. By 12 weeks, 40.8% of those on the 200 milligram dose of filgotinib and 37.3% of those on 100 milligrams had reached the status of low disease activity as measured by the DAS28-CRP, as opposed to only 15.5% of those on the placebo regimen. These outcomes continued or improved over the course of the trial. By 24 weeks, 48.3% of the high-dose filgotinib recipients and 37.9% of those on the low dose had reached low-disease-activity status.
By week 12 of the trial, 22.4% of high-dose and 25.5% of low-dose filgotinib recipients, but only 8.1% of placebo recipients, had DAS28-CRP scores indicating outright remission. By week 24, high-dose recipients had a remission rate of 30.6%; low-dose recipients, 26.1%; and placebo recipients, 12.2%.
Improvement seen early on
The drug’s benefits to participants became apparent soon after the trial’s onset. “We could see improvements as early as two weeks into the trial,” Genovese said.
Also telling was a substantial difference among the study arms in how many participants completed the 24-week trial. Of the 148 participants in the placebo arm, 51 dropped out before completion. Only 20 of the 148 high-dose recipients and 34 of the 153 low-dose recipients dropped out.
Investigators’ early concerns about increased susceptibility to infections, or the re-emergence of active forms of prior infections, such as tuberculosis or shingles, were assuaged by the relative smattering of such adverse events, compared with placebo.
Notably, patients for whom at least three different biologic therapies provided insufficient relief did as well in this trial as those who’d derived insufficient relief from just one biologic therapy, Genovese said. “We found that those high levels of response were independent of how many drugs you’d failed, and independent of which drugs you’d failed,” he said.
Overall response rates to filgotinib appear to surpass those of the other commercially available JAK inhibitors at doses approved for use in the United States, he said.
“This novel drug works exceptionally well in patients who’ve already failed traditional therapies for rheumatoid arthritis,” he said.
The Latest on: Rheumatoid arthritis
via Google News
The Latest on: Rheumatoid arthritis
- FDA approves Humira maker AbbVie's new rheumatoid arthritis drugon August 16, 2019 at 10:30 am
The drug, Rinvoq, belongs to a class of drugs known as JAK inhibitors that block inflammation-causing enzymes called Janus kinases. It is set to compete with Pfizer's Xeljanz and Eli Lilly's Olumiant.
- AbbVie Receives FDA Approval of RINVOQ™ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritison August 16, 2019 at 10:00 am
- RINVOQ (upadacitinib) met all primary and ranked secondary endpoints across a variety of patients with moderately to severely active rheumatoid arthritis[1-7] - Durable remission rates with ...
- FDA approves AbbVie's new rheumatoid arthritis drugon August 16, 2019 at 9:43 am
(Reuters) - The U.S. Food and Drug Administration on Friday approved AbbVie Inc’s new treatment for rheumatoid arthritis, a win for the drugmaker seeking to widen its portfolio as its blockbuster ...
- Woman who uses cannabis to treat arthritis urges doctors to prescribe to patients in needon August 16, 2019 at 1:16 am
Pearl Schomburg uses cannabis to treat rheumatoid arthritis. "Cannabis balm was the first thing I discovered and was shocked by how well it worked," she told Newshub. She's urging doctors to put their ...
- EMA accepts Gilead's filgotinib application for rheumatoid arthritison August 15, 2019 at 6:17 pm
Gilead Sciences (GILD-0.4%) and collaboration partner Galapagos NV (GLPG) announce that the European Medicines Agency (EMA) has accepted for review their marketing application for JAK1 inhibitor ...
- European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Rheumatoid Arthritison August 15, 2019 at 3:48 pm
Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 ...
- Rheumatoid arthritis may start in the lungs rather than jointson August 15, 2019 at 5:02 am
ORLANDO — A line of progression from disease susceptibility to overt rheumatoid arthritis could potentially begin with environmental factors in the lungs, as well as the gingiva, according to a ...
- A Simple Energy Boost for People With Rheumatoid Arthritison August 13, 2019 at 4:23 pm
If you’ve lived with rheumatoid arthritis (RA) even for a short time, you know the trademark fatigue that comes with it. It’s the kind of mental and physical exhaustion that can’t be cured by a good ...
- Complete remission of seronegative rheumatoid arthritis following haplo-identical stem cell transplantation for peripheral T-cell lymphomaon August 12, 2019 at 6:51 am
All prices are NET prices. VAT will be added later in the checkout. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an ...
- Rheumatoid Arthritis Therapeutics Market Size, Share, Key Players Overview and Geographical Outlook 2026on August 8, 2019 at 2:58 am
Aug 08, 2019 (The Expresswire) -- Rheumatoid Arthritis Therapeutics Market Size, Share and Global Trend By Product Type (Biologics, Non-Biologics), Distribution Channels (Hospital Pharmacy, Retail ...
via Bing News